Nexstim Revenue and Competitors

Helsinki, Finland

Location

$35.8M

Total Funding

Estimated Revenue & Valuation

  • Nexstim's estimated annual revenue is currently $7M per year.(i)
  • Nexstim's estimated revenue per employee is $125,500
  • Nexstim's total funding is $35.8M.

Employee Data

  • Nexstim has 56 Employees.(i)
  • Nexstim grew their employee count by -7% last year.

Nexstim's People

NameTitleEmail/Phone
1
ControllerReveal Email/Phone
2
Director Business DevelopmentReveal Email/Phone
3
Director, NeuroscienceReveal Email/Phone
4
Clinical Application SpecialistReveal Email/Phone
5
Field Services EngineerReveal Email/Phone
6
Business Development Sales ManagerReveal Email/Phone
7
Sr Sales RepresentativeReveal Email/Phone
8
Trainee, Quality and Regulatory AffairsReveal Email/Phone
9
Office Assistant TraineeReveal Email/Phone
10
Clinical Application SpecialistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$127.2M3776%N/AN/A
#2
$88.8M2834%$313.4MN/A
Add Company

What Is Nexstim?

Nexstim is the world leader in image-guided transcranial magnetic stimulation (TMS) Founded in 2000 in Helsinki, Finland, Nexstim is committed to improving the quality of life of patients with significant unmet clinical needs by helping to preserve what is vital. Nexstim has pioneered the technology for brain diagnostics and holds the only FDA-clearances for non-invasive pre-surgical mapping with the Navigated Brain Stimulation (NBS) System for the primary motor cortex and NexSpeech® for speech and language function. NBS is recognized as the emerging standard for pre-operative direct functional mapping. NBS Makes TMS Visible Nexstim's technology introduces navigated transcranial magnetic stimulation (nTMS) for pre-surgical non-invasive mapping. The navigation is based on the patient´s MRI scan and proprietary electric field modeling, allowing the NBS System to uniquely show the location and orientation of TMS-stimuli inside the brain. NBS and NexSpeech® accurately and reliably maps the brain's vital functions like a GPS maps the globe. Nexstim offers a comfortable and safe method for brain mapping in adults or children with a diagnosis of tumor or epilepsy. The Difference is Accuracy The NBS System is as accurate as the "gold standard" of intraoperative direct cortical stimulation (DCS). Multiple papers have shown that Nexstim's NBS mappings are more accurate than fMRI and MEG. Mapping results may enable more patients to be offered a surgical option, and eliminate surgical candidates before they go into the OR. NBS data leads to better planning for a more complete tumor resection, offering smaller craniotomies and less time in the OR. Better planning leads to decreasing the risk of damage to the eloquent cortex, thereby preserving a patient's vital function.

keywords:N/A

$35.8M

Total Funding

56

Number of Employees

$7M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Nexstim News

2022-04-19 - Nexstim Plc Business and Clinical Update Q1 2022

Nexstim is a Finnish, globally operating and growth-oriented medical technology company. Our mission is to enable personalised and effective...

2022-04-06 - Nexstim Plc: Managers' Transactions, Niemistö

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective...

2022-03-30 - Nexstim Receives an NBS 5+ System Order from a US Customer

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective...

2019-09-08 - Achieve TMS, the second largest TMS group in the US, starts ...

Dr. Shashita Inamdar from Achieve TMS said: “We are pleased to start offering the Nexstim NBT® system with SmartFocus® technology to our ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.3M56-11%N/A
#2
$10.3M5619%N/A
#3
$7.3M562%N/A
#4
$7.2M5719%N/A
#5
$11.3M5721%N/A